Cargando…

FXR antagonism of NSAIDs contributes to drug-induced liver injury identified by systems pharmacology approach

Non-steroidal anti-inflammatory drugs (NSAIDs) are worldwide used drugs for analgesic, antipyretic, and anti-inflammatory therapeutics. However, NSAIDs often cause several serious liver injuries, such as drug-induced liver injury (DILI), and the molecular mechanisms of DILI have not been clearly elu...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Weiqiang, Cheng, Feixiong, Jiang, Jing, Zhang, Chen, Deng, Xiaokang, Xu, Zhongyu, Zou, Shien, Shen, Xu, Tang, Yun, Huang, Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4310094/
https://www.ncbi.nlm.nih.gov/pubmed/25631039
http://dx.doi.org/10.1038/srep08114
_version_ 1782354804175011840
author Lu, Weiqiang
Cheng, Feixiong
Jiang, Jing
Zhang, Chen
Deng, Xiaokang
Xu, Zhongyu
Zou, Shien
Shen, Xu
Tang, Yun
Huang, Jin
author_facet Lu, Weiqiang
Cheng, Feixiong
Jiang, Jing
Zhang, Chen
Deng, Xiaokang
Xu, Zhongyu
Zou, Shien
Shen, Xu
Tang, Yun
Huang, Jin
author_sort Lu, Weiqiang
collection PubMed
description Non-steroidal anti-inflammatory drugs (NSAIDs) are worldwide used drugs for analgesic, antipyretic, and anti-inflammatory therapeutics. However, NSAIDs often cause several serious liver injuries, such as drug-induced liver injury (DILI), and the molecular mechanisms of DILI have not been clearly elucidated. In this study, we developed a systems pharmacology approach to explore the mechanism-of-action of NSAIDs. We found that the Farnesoid X Receptor (FXR) antagonism of NSAIDs is a potential molecular mechanism of DILI through systematic network analysis and in vitro assays. Specially, the quantitative real-time PCR assay reveals that indomethacin and ibuprofen regulate FXR downstream target gene expression in HepG2 cells. Furthermore, the western blot shows that FXR antagonism by indomethacin induces the phosphorylation of STAT3 (signal transducer and activator of transcription 3), promotes the activation of caspase9, and finally causes DILI. In summary, our systems pharmacology approach provided novel insights into molecular mechanisms of DILI for NSAIDs, which may propel the ways toward the design of novel anti-inflammatory pharmacotherapeutics.
format Online
Article
Text
id pubmed-4310094
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-43100942015-02-09 FXR antagonism of NSAIDs contributes to drug-induced liver injury identified by systems pharmacology approach Lu, Weiqiang Cheng, Feixiong Jiang, Jing Zhang, Chen Deng, Xiaokang Xu, Zhongyu Zou, Shien Shen, Xu Tang, Yun Huang, Jin Sci Rep Article Non-steroidal anti-inflammatory drugs (NSAIDs) are worldwide used drugs for analgesic, antipyretic, and anti-inflammatory therapeutics. However, NSAIDs often cause several serious liver injuries, such as drug-induced liver injury (DILI), and the molecular mechanisms of DILI have not been clearly elucidated. In this study, we developed a systems pharmacology approach to explore the mechanism-of-action of NSAIDs. We found that the Farnesoid X Receptor (FXR) antagonism of NSAIDs is a potential molecular mechanism of DILI through systematic network analysis and in vitro assays. Specially, the quantitative real-time PCR assay reveals that indomethacin and ibuprofen regulate FXR downstream target gene expression in HepG2 cells. Furthermore, the western blot shows that FXR antagonism by indomethacin induces the phosphorylation of STAT3 (signal transducer and activator of transcription 3), promotes the activation of caspase9, and finally causes DILI. In summary, our systems pharmacology approach provided novel insights into molecular mechanisms of DILI for NSAIDs, which may propel the ways toward the design of novel anti-inflammatory pharmacotherapeutics. Nature Publishing Group 2015-01-29 /pmc/articles/PMC4310094/ /pubmed/25631039 http://dx.doi.org/10.1038/srep08114 Text en Copyright © 2015, Macmillan Publishers Limited. All rights reserved http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder in order to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Article
Lu, Weiqiang
Cheng, Feixiong
Jiang, Jing
Zhang, Chen
Deng, Xiaokang
Xu, Zhongyu
Zou, Shien
Shen, Xu
Tang, Yun
Huang, Jin
FXR antagonism of NSAIDs contributes to drug-induced liver injury identified by systems pharmacology approach
title FXR antagonism of NSAIDs contributes to drug-induced liver injury identified by systems pharmacology approach
title_full FXR antagonism of NSAIDs contributes to drug-induced liver injury identified by systems pharmacology approach
title_fullStr FXR antagonism of NSAIDs contributes to drug-induced liver injury identified by systems pharmacology approach
title_full_unstemmed FXR antagonism of NSAIDs contributes to drug-induced liver injury identified by systems pharmacology approach
title_short FXR antagonism of NSAIDs contributes to drug-induced liver injury identified by systems pharmacology approach
title_sort fxr antagonism of nsaids contributes to drug-induced liver injury identified by systems pharmacology approach
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4310094/
https://www.ncbi.nlm.nih.gov/pubmed/25631039
http://dx.doi.org/10.1038/srep08114
work_keys_str_mv AT luweiqiang fxrantagonismofnsaidscontributestodruginducedliverinjuryidentifiedbysystemspharmacologyapproach
AT chengfeixiong fxrantagonismofnsaidscontributestodruginducedliverinjuryidentifiedbysystemspharmacologyapproach
AT jiangjing fxrantagonismofnsaidscontributestodruginducedliverinjuryidentifiedbysystemspharmacologyapproach
AT zhangchen fxrantagonismofnsaidscontributestodruginducedliverinjuryidentifiedbysystemspharmacologyapproach
AT dengxiaokang fxrantagonismofnsaidscontributestodruginducedliverinjuryidentifiedbysystemspharmacologyapproach
AT xuzhongyu fxrantagonismofnsaidscontributestodruginducedliverinjuryidentifiedbysystemspharmacologyapproach
AT zoushien fxrantagonismofnsaidscontributestodruginducedliverinjuryidentifiedbysystemspharmacologyapproach
AT shenxu fxrantagonismofnsaidscontributestodruginducedliverinjuryidentifiedbysystemspharmacologyapproach
AT tangyun fxrantagonismofnsaidscontributestodruginducedliverinjuryidentifiedbysystemspharmacologyapproach
AT huangjin fxrantagonismofnsaidscontributestodruginducedliverinjuryidentifiedbysystemspharmacologyapproach